<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92489">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01900899</url>
  </required_header>
  <id_info>
    <org_study_id>200088</org_study_id>
    <secondary_id>2012-005816-25</secondary_id>
    <nct_id>NCT01900899</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Persistence of Antibodies After GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children</brief_title>
  <official_title>Persistence of Antibodies After GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term antibody persistence as well as
      safety of GSK Biologicals' MenACWY-TT vaccine versus Meningitec up to 6 years after booster
      vaccination administered in healthy 5 year old children in the study MENACWY-TT-048 EXT: 039
      Y2, 3, 4, 5 (NCT00955682), who were primed with the same vaccine in the study MENACWY-TT-039
      (NCT00474266) at 12 through 23 months of age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The subjects in this study will be allocated to the same groups as in study MENACWY-TT-048
      EXT: 039 Y2, 3, 4, 5 (NCT00955682). No vaccine will be administered during this long-term
      persistence study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Persistence of antibodies with respect to components of the investigational vaccine in terms of antibody titres.</measure>
    <time_frame>2, 3, 4, 5, 6 years after booster vaccination.</time_frame>
    <description>rSBA-MenA, rSBA- MenC, rSBA-MenW-135 and rSBA-MenY titres.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Persistence of antibodies with respect to components of the investigational vaccine in terms of antibody titres.</measure>
    <time_frame>2, 3, 4, 5, 6 years after booster vaccination.</time_frame>
    <description>rSBA-MenA, rSBA-MenC, rSBA-MenW-135, rSBA-MenY, hSBA-MenA, hSBA-MenC, hSBA-MenW-135, hSBA-MenY titres and GMTs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events (SAEs).</measure>
    <time_frame>From the subject's last visit in study MENACWY-TT-048 EXT: 039 Y2, 3, 4, 5 (NCT00955682) up to each yearly visit in the current study (i.e. 2, 3, 4, 5 and 6 years post booster vaccination).</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">173</enrollment>
  <condition>Infections, Meningococcal</condition>
  <arm_group>
    <arm_group_label>ACWY-TT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects primed and boosted with the MenACWY-TT vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenCCRM group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects primed and boosted with the Meningitec vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Sampling</intervention_name>
    <description>At 2, 3, 4, 5, 6 years after booster vaccination.</description>
    <arm_group_label>ACWY-TT group</arm_group_label>
    <arm_group_label>MenCCRM group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects must satisfy ALL the following criteria at study entry:

          -  Subjects' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion
             of the investigator, can and will comply with the requirements of the protocol.

          -  A male or female who has received primary and booster vaccination with the MenACWY-TT
             or Meningitec vaccines in studies MENACWY-TT-039 (109670) and MENACWY-TT-048 EXT: 039
             Y2, 3, 4, 5 (112036), respectively.

          -  Written informed consent obtained from the parent(s)/LAR(s) of the subject.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

        Exclusion Criteria:

        The following criteria should be checked at the time of study entry. If ANY exclusion
        criterion applies, the subject must not be included in the study:

          -  Child in care.

          -  History of meningococcal disease.

          -  Administration of a meningococcal polysaccharide or a meningococcal polysaccharide
             conjugate vaccine outside of studies MENACWY-TT-039 (109670) and MENACWY-TT-048 EXT:
             039 Y2, 3, 4, 5 (112036).

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  Bleeding disorders, such as thrombocytopenia, or subjects on anti-coagulant therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Espoo</city>
        <zip>02230</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jarvenpaa</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seinajoki</city>
        <zip>60100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vantaa</city>
        <zip>01300</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>February 4, 2016</lastchanged_date>
  <firstreceived_date>June 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Children</keyword>
  <keyword>Neisseria meningitidis</keyword>
  <keyword>Long-term antibody persistence</keyword>
  <keyword>Safety</keyword>
  <keyword>Serogroups A, C, W-135, and Y</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
